KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Operating Leases (2019 - 2025)

Acadia Pharmaceuticals has reported Operating Leases over the past 7 years, most recently at $40.6 million for Q4 2025.

  • Quarterly results put Operating Leases at $40.6 million for Q4 2025, down 3.53% from a year ago — trailing twelve months through Dec 2025 was $40.6 million (down 3.53% YoY), and the annual figure for FY2025 was $40.6 million, down 3.53%.
  • Operating Leases for Q4 2025 was $40.6 million at Acadia Pharmaceuticals, down from $43.0 million in the prior quarter.
  • Over the last five years, Operating Leases for ACAD hit a ceiling of $60.6 million in Q1 2021 and a floor of $40.4 million in Q3 2024.
  • Median Operating Leases over the past 5 years was $49.5 million (2023), compared with a mean of $49.9 million.
  • Biggest five-year swings in Operating Leases: soared 943.11% in 2021 and later fell 15.97% in 2024.
  • Acadia Pharmaceuticals' Operating Leases stood at $56.1 million in 2021, then dropped by 6.11% to $52.7 million in 2022, then dropped by 9.29% to $47.8 million in 2023, then dropped by 12.06% to $42.0 million in 2024, then dropped by 3.53% to $40.6 million in 2025.
  • The last three reported values for Operating Leases were $40.6 million (Q4 2025), $43.0 million (Q3 2025), and $44.6 million (Q2 2025) per Business Quant data.